ProCE Banner Activity

Phase II Study of Hyper-CVAD + Blinatumomab in Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell ALL

Slideset Download
Conference Coverage
Hyper-CVAD + blinatumomab shows promising activity with both high response rates and deep responses in patients with newly diagnosed B-cell ALL in this phase II study.

Released: December 11, 2020

Expiration: December 10, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology